Lenz Therapeutics stock rises after FDA approves presbyopia eye drops

Investing.com -- Lenz Therapeutics Inc (NASDAQ: LENZ) stock rose 3.3% following FDA approval of VIZZ, the first aceclidine-based eye drop treatment for presbyopia in adults.

The company announced that VIZZ (aceclidine ophthalmic solution) 1.44% received FDA approval as the first and only aceclidine-based eye drop for treating blurry near vision. Lenz plans to make samples available in the United States as early as October 2025, with commercial product broadly available by mid-fourth quarter 2025.

VIZZ features aceclidine as its active ingredient, which works as a predominantly pupil-selective miotic that contracts the iris sphincter muscle. This creates a pinhole effect that extends depth of focus to improve near vision without causing a myopic shift. Aceclidine represents a new chemical entity in the United States, with this approval marking its first global use for presbyopia treatment.

The FDA approval was based on results from three randomized, double-masked, controlled Phase 3 studies involving over 680 participants. In the CLARITY 1 and CLARITY 2 trials, VIZZ demonstrated the ability to improve near vision within 30 minutes with effects lasting up to 10 hours.

"The FDA approval of VIZZ is a defining moment for LENZ and represents a transformative improvement in the available treatment options for the 128 million adults living with blurry near vision in the United States," said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics.

The company reported that VIZZ was well-tolerated in clinical trials, with the most common adverse reactions being installation site irritation, dim vision, and headache. The majority of these reactions were described as mild, transient, and self-resolving.

You May Also Be Interested In

• Samsara Inc (IOT) call put ratio 4.5 calls to 1 put with a focus on September 4 weekly calls into quarter results
• The Retirement Risk That Can Derail Even the Best Financial Plan
• CrowdFlowCo Expands Agritourism Marketing Program, Says Seasonal Venues Are Marketing in the Wrong Season